UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/591,827	10/10/2006	Masahiro Yamauchi	2006_1488A	4401
	7590 06/21/201 , LIND & PONACK, I	EXAMINER		
1030 15th Street, N.W., Suite 400 East Washington, DC 20005-1503			EPPS -SMITH, JANET L	
			ART UNIT	PAPER NUMBER
			1633	
			NOTIFICATION DATE	DELIVERY MODE
			06/21/2010	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

ddalecki@wenderoth.com eoa@wenderoth.com

Office Action Summary		Application No.	Applicant(s)	Applicant(s)	
		10/591,827	YAMAUCHI ET	AL.	
		Examiner	Art Unit		
		Janet L. Epps-Smith	1633		
The MAILING DATE of this c Period for Reply	ommunication app	ears on the cover shee	et with the correspondence	address	
A SHORTENED STATUTORY PER WHICHEVER IS LONGER, FROM - Extensions of time may be available under the after SIX (6) MONTHS from the mailing date of the state of t	THE MAILING DA provisions of 37 CFR 1.13 this communication. aximum statutory period w d for reply will, by statute, e months after the mailing	ATE OF THIS COMMU 16(a). In no event, however, m ill apply and will expire SIX (6) cause the application to becor	UNICATION. ay a reply be timely filed MONTHS from the mailing date of this ne ABANDONED (35 U.S.C. § 133).		
Status					
Responsive to communication This action is FINAL . Since this application is in concluded in accordance with the conclusion.	2b)⊡ This andition for allowan	action is non-final. ace except for formal r	•	he merits is	
Disposition of Claims					
4)	is/are withdraw d. is/are rejected. ed to.	vn from consideration			
Application Papers					
9) The specification is objected 10) The drawing(s) filed on Applicant may not request that a Replacement drawing sheet(s) in 11) The oath or declaration is obj	_ is/are: a) ☐ acce any objection to the c ncluding the correction	epted or b) objected drawing(s) be held in abo on is required if the draw	eyance. See 37 CFR 1.85(a). wing(s) is objected to. See 37	CFR 1.121(d).	
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a a) All b) Some * c) No 1. Certified copies of the 2. Certified copies of the	ne of: priority documents priority documents copies of the priori ternational Bureau	s have been received. s have been received ity documents have b (PCT Rule 17.2(a)).	in Application No een received in this Nation	al Stage	
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing F 3) Information Disclosure Statement(s) (PTO Paper No(s)/Mail Date		Paper 5) Notice	iew Summary (PTO-413) No(s)/Mail Date e of Informal Patent Application		

Application/Control Number: 10/591,827 Page 2

Art Unit: 1633

DETAILED ACTION

1. Claims 1-38, 41, 43-47 and 49 were cancelled by Applicants. Claims 39-40, 42 and 48, 50 are pending for examination.

2. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Response to Arguments

Claim Rejections - 35 USC § 102

3. The rejection of claims 39-40, 42, and 48-50 under 35 U.S.C. 102(b) as being anticipated by Kato et al. (US20040022938), is withdrawn in response to Applicant's amendment.

Claim Rejections - 35 USC § 103

- 4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 5. Claims 39-40, 42, 48 and 50 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kato et al. (US20040022938).
- 6. Applicant's arguments filed 03/17/2010 have been fully considered but they are not persuasive. Applicants traversed the rejection of the instant claims over Kato et al. on the grounds that (1) Kato does not expressly teach the combination of a nucleic acid and an anionic polymer with liposome; or (2) Kato et al. does not disclose plasmids and siRNA. Furthermore, Applicants refer to Examples 13 and 15-17 to conclude that

Art Unit: 1633

coating of the complex particles with the coating lipid is efficient, and therefore is preferred to the preparation of Example 13 (without anionic polymer).

Contrary to Applicant's assertions, although Kato et al. does not expressly describe a complex of plasmid or siRNA, liposome and anionic polymer, Kato et al. discloses a method for coating fine particles with lipid membrane, wherein the fine particles comprise a complex of a drug, liposome containing phospholipid and a dextran sulfate sodium salt, (¶ [0020]). Furthermore, Kato et al. teaches wherein the drug is a nucleic acid, and further wherein said nucleic acid is a gene (see ¶ [0030]), antisense oligonucleotide, sense oligonucleotide, DNA and RNA. Absent evidence to the contrary, it would have been obvious to substitute alternative, structurally equivalent forms of nucleic acid, such as plasmid or siRNA for the forms of nucleic acid used in the complexes of Kato et al. It is clear that the novelty of the claimed invention is not associated with the class of nucleic acid, as evidenced by ¶ [0018] of the specification as filed, which recites: "[T]he method of inhibiting aggregation of complex particles according to the above (8), wherein the nucleic acid as the drug is one or more substance(s) selected from genes, DNA, RNA, oligonucleotides, plasmids and siRNA." Therefore, the selection of plasmid or siRNA as the nucleic acid in the complexes of the claimed invention is simply a matter of design choice.

Additionally, in regards to the increase in efficiency observed due to the presence of anionic polymer in Examples 15-17 of the specification as filed, Applicants have not provided any evidence that this observation is unexpected in light of the teachings of Kato et al.

Application/Control Number: 10/591,827 Page 4

Art Unit: 1633

Conclusion

7. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Application/Control Number: 10/591,827

Art Unit: 1633

8. Any inquiry concerning this communication or earlier communications from the

Page 5

examiner should be directed to Janet L. Epps-Smith whose telephone number is 571-

272-0757. The examiner can normally be reached on M-F, 10:00 AM through 6:30 PM.

9. If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Joseph Woitach can be reached on 571-272-0739. The fax phone number

for the organization where this application or proceeding is assigned is 571-273-8300.

10. Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a

USPTO Customer Service Representative or access to the automated information

system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Janet L. Epps-Smith/

Primary Examiner, Art Unit 1633